Tilray (TLRY) shows signs of weak growth moving forward
Tilray (TLRY) currently trades at $6.72 and has fallen by 4.55% today. TLRY went down $0.32 from the previous closing price of $7.04. The high forecast for Tilray is $28.00 and the low is $2.00. The company’s market cap is $739.41 million with a 52 week high of $54.10 and a 52 week low of $2.43. TLRY has changed in price by -42.52 per share in the last 12 months. Tilray’s Q4 2019 revenue of $167 million has doubled from Q4 2019, net losses have worsened substantially. The cannabis company reported a $219.1 million net loss, although about $112.1 million of that was due to a one-time impairment charge related to its partnership with Authentic Brands Group. Tilray also reported a $68.6 million impairment to its inventory reserves, which further pushed down the quarter’s net losses.
Tilray has a weak EPS of -3.2. This means the company lost $-3.2 per share after paying dividends, this can indicate that the stock is a risky investment. EPS is calculated as a company’s profit divided by the outstanding shares of its common stock. The resulting number serves as an indicator of a company’s profitability. It is common for a company to report EPS that is adjusted for extraordinary items and potential share dilution. Based on this information, investorsQ rates this stock 2 out of 10. We give it this rating based on current information written in this article.
Tilray is a global leader in cannabis research, cultivation, processing and distribution. We aspire to lead, legitimize and define the future of our industry by building the world’s most trusted cannabis and hemp company.